Pueraria candollei is a phytoestrogen-rich herb used to treat estrogen deficiency disorders; however, quality control of P. candollei-related health products is required for consistency of clinical outcomes. Estrogenically active (+)-7-O-methylisomiroestrol could be a potential chemical marker that facilitates the prediction of the overall estrogenic activity of P. candollei. The analytical performance of ELISA using newly produced monoclonal antibodies against methylisomiroestrol was compared with HPLC analysis. The developed indirect competitive ELISA (icELISA) was highly sensitive to methylisomiroestrol for detection, with an LOQ of 2.9 ng/mL, whereas the LOQ was 1.15 μg/mL by HPLC. The results from method validation indicated acceptable precision (1.71-6.37 % and 0.13-2.40 %) and accuracy (99.23-102.54 % and 96.84-101.88 %) of the methylisomiroestrol analysis using icELISA and HPLC. These methods were effectively applied for the determination of the methylisomiroestrol content in P. candollei samples. Apart from the plant tubers, the stem was observed as a source of methylisomiroestrol. The developed ELISA was more effective than HPLC in detecting a small quantity of methylisomiroestrol in the plant samples [0.23 × 10-3% (w/w) to 0.628 × 10-3% (w/w) dry weight]. Therefore, the ELISA could be a useful tool for the standardization of P. candollei, which is the crucial step to improve the quality of plant-derived products.
  This study aimed to investigate the long-term outcomes of patients with convulsive epilepsy in rural West China and to explore potential related factors.
 
  Patients who were provided Phenobarbital as a treatment and followed-up monthly were enrolled from the Convulsive Epilepsy Control and Management Program in West China. Their clinical and demographic information were obtained from the program database and a questionnaire. Seizure outcomes, comorbidities, annual income, marital status, employment and quality of life (QOL) were evaluated as long-term outcomes. Logistic regression was used to analyze the related factors.
 
  Of 473 eligible patients with a median follow-up time of nearly 7 years, 312 (66 %) had one-year terminal remission. A total of 320 (67.7 %) patients had a low annual income (<5000 Yuan), and 198 (41.9 %) patients reported a comorbidity. Among 460 patients of marriageable age, 137 (29.8 %) were unmarried. 60.4 % (333) patients reported improved QOL. Time of follow-up, seizure frequency during early treatment, compliance, annual cost for epilepsy treatment and annual income were related to the seizure outcome.  https://www.selleckchem.com/products/GDC-0449.html  Baseline seizure frequency was associated with comorbidities. Sex, annual cost for epilepsy treatment and seizure outcomes were associated with annual income. Age, sex and age at onset were correlated with current marital status. Compliance and taking traditional Chinese medicine were associated with QOL.
 
  The prognosis of epilepsy goes beyond being seizure-free. Comorbidities, income and marriage outcomes in resource-poor areas are less promising. Systematic management considering prognosis-related factors for epilepsy by a collaboration of health providers and society is needed.
 The prognosis of epilepsy goes beyond being seizure-free. Comorbidities, income and marriage outcomes in resource-poor areas are less promising. Systematic management considering prognosis-related factors for epilepsy by a collaboration of health providers and society is needed.
  To examine the relationship between epilepsy and sudden cardiac arrest (SCA) and identify clinical and healthcare system related predictors of SCA in patients with a discharge diagnosis of epilepsy undergoing continuous video EEG (cVEEG) monitoring.
 
  The national inpatient sample was used as data source to identify adults (18 years and older) with a primary discharge diagnosis of epilepsy who were at some point during their hospitalization on cVEEG monitoring. We applied a logistic regression model to identify independent patient-related and hospital/healthcare system-related factors associated with SCA.
 
  A total of weighted 10,059 (0.71 %) patients with epilepsy on cVEEG had a secondary discharge diagnosis of SCA. The main independent factors associated with SCA were the presence of any of the following secondary discharge diagnoses paroxysmal arrhythmia (OR 2.29, 95 %CI 1.96-2.66), myocardial infarction (OR 3.78, 95 %CI 2.83-5.05), congestive heart failure (OR 2.27, 95 %CI 1.93-2.62), and anoxic brain injury (OR 57.6, 95 %CI 50.83-67.27). There was no association between refractory epilepsy and SCA (OR 0.99, 95 %CI 0.51-1.93).
 
  SCA is a rare event occurring in < 1% of patients with epilepsy undergoing cVEEG monitoring in the United States. Key independent contributors to occurrence of SCA are presence of select cardiovascular conditions and anoxic brain injury.
 SCA is a rare event occurring in less then 1% of patients with epilepsy undergoing cVEEG monitoring in the United States. Key independent contributors to occurrence of SCA are presence of select cardiovascular conditions and anoxic brain injury.
  Delirium is frequently observed in the postoperative and intensive care unit (ICU) population. Due to the multifactorial origin of delirium and according to international guidelines (e.g., American Geriatrics Society; Prevention and Management of Pain, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption (PADIS) guideline), there are several but no incontestable options for prevention and symptomatic treatment. The purpose of the Baden PRIDe (Prevention and Reduction of Incidence of postoperative Delirium) trial was to determine whether postoperative cognitive dysfunction and delirium could be prevented by the combination of possible preventive agents such as haloperidol and ketamine. In addition, pre- and postoperative levels of the biomarkers cortisol, neuron specific enolase (NSE) and S100β were measured to investigate their dynamics in delirious and non-delirious patients after surgery.
 
  The Baden PRIDe Trial was an investigator-initiated, phase IV, two-centre, randomised, placebo-controlled, double-blind clinical trial.